


Financial/Non-Financial Highlights 2019/4-2020/3


Financial Information

Revenue (Millions of Yen)




Increased by 1.3% year-on-year due to increased royalty revenue and expanded sales of new key products offsetting the negative impact of the OPDIVO price revision in Japan and increased competition with competitors.

Operating profit (Millions of Yen)




Increased by 25.0% year-on-year due to increased revenue, together with decreased sales costs and R&D costs as well as decreased operating activity expenses because of the novel coronavirus infectious disease (COVID-19).

Profit for the year attributable to owners of the parent company (Millions of Yen)




Net financial income decreased from the previous year but the profit before tax increased by 15.8% compared to the previous year due to increased operating profit.

R&D costs / Ratio to revenue (Millions of Yen / %)




Decreased by 5.0% year-on-year due to decreased clinical trial expenses because of reevaluation of clinical study plans and discontinuation of some clinical studies, as well as decreased license fees for drug discovery alliance.

Basic earnings per share (Yen)




Dividend per share / Consolidated payout ratio (Yen / %)



ONO considers the redistribution of profits to shareholders as a vital management policy. ONO will prioritize stable dividend distribution, making appropriate distribution of its profits in line with its business performance.

Non-Financial Information


Number of employees



We recruit not only new graduates but also midcareer workers and others with a variety of different backgrounds to strengthen our corporate infrastructure.

► Human Resources and Human Rights, p. 47


Number of female employees / Ratio of female to male workforce



As part of diversity promotion initiatives, we have made efforts to promote women's participation and advancement in the workplace, and female employees have increased in number across all divisions since 2011.

► Human Resources and Human Rights, p. 47


Participation record for "Relay For Life" as part of CSR activities



Since FY2014, we have continuously participated in "Relay For Life," a charity event aimed at supporting cancer patients and their families and making cancer controllable and surmountable through community action against cancer.

► Corporate Social Responsibility (CSR) Activities, p. 50


Meetings with institutional investors (personal interviews/phone conferences)



We disseminate information based on the policy of pursuing accuracy, fairness, impartiality, and promptness. We actively hold personal interviews and phone conferences with investors inside and outside Japan.

► Information Disclosure, p. 58

Comprehensive medical examination rate (FY2019)




We take a top-down approach to actively maintaining and enhancing the health of employees and their families. We have a support system in place for disease prevention, early detection, and treatment.

► Promotion of Health and Productivity Management, p. 45

Eligibility: Insured employees age 35 and over, and their dependent spouses

CO₂ emissions (10 thousand tons-CO₂)



In accordance with our environmental policy, we set and work to achieve numerical targets.

► Environment, p. 39